Clinical studies have shown TIM-1 expression: to be significantly higher than normal in the plasma of patients with benign and malignant renal tumours; increased significantly with disease stage; to be significantly lower in patients with benign tumours than in patients with malignant tumours (Mijuskovic et al., 2018; Kushlinskii et al., 2019). This evidence concerns the gene HAVCR1 and cancer.